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Anti-HMGB1 auto-Abs influence fatigue
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Abstract
Fatigue is common in all chronic inflammatory and autoimmune diseases. A conceptual model for understanding the
biological basis of fatigue describes it as being a part of the sickness behaviour response generated by pro-inflammatory
cytokines and other mediators. We hypothesised that the pro-inflammatory high mobility group box 1 (HMGB1) protein
is a fatigue-inducing molecule and that auto-Abs against HMGB1 reduce fatigue. We measured Abs against disulphide
(ds) HMGB1 and fully reduced (fr) HMGB1 in plasma from 57 patients with Crohn’s disease. Fatigue was rated using the
fatigue visual analogue scale (fVAS) and disease activity with faecal calprotectin, C-reactive protein and the Simple
Endoscopic Score for Crohn’s disease. Multivariable regression models identified anti-dsHMGB1 and anti-frHMGB1
Abs as the strongest contributing factors for fVAS scores (B¼29.10 (P¼ 0.01), R2¼ 0.17, and B¼17.77 (P¼ 0.01),
R2¼ 0.17, respectively). Results indicate that anti-HMGB1 auto-Abs alleviate fatigue possibly by down-regulating
HMGB1-induced sickness behaviour.
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Introduction
High mobility group box 1 (HMGB1) is a non-histone
chromatin-binding protein abundantly found in all cell
nuclei and is composed of 215 aa with two DNA-
binding domains (A and B boxes) as well as an
acidic, negatively charged C-terminal.1 This evolution-
arily well-conserved protein2 serves fundamental and
divergent tasks both intracellularly and extracellularly.
In the nuclei of resting cells, HMGB1 regulates DNA
transcription and organisation of DNA and nucleo-
somes, but in this state, it has no known immune func-
tion.3 Cell stress, cellular injury or pathogens may
stimulate HMGB1 translocation from the nucleus to
the cytoplasm and subsequent release into the extracel-
lular space.4
HMGB1 contains three conserved redox-sensitive
cysteines, and the bioactivity of HMGB1 is dependent
on modifications of these cysteine residues. The protein
plays a key role in the clearance of various bacterial
and viral infections and enhances rapid clearing of
intracellular pathogens and endogenous damage-
associated molecular patterns (DAMPs).
When macrophages and monocytes directly encoun-
ter pathogens or DAMPs, HMGB1 is actively secreted
into extracellular space by the immune cells. The pro-
tein activates TLR4 and elicits strong activation of
innate immune cells and inflammatory responses.5–7
Many clinical studies have described the central role
of HMGB1 in inflammation, and recent studies have
also pointed out its potential as a therapeutic target.8
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Increased blood concentrations of HMGB1 are
observed during infections and in chronic inflammato-
ry and autoimmune diseases.9 In patients with systemic
lupus erythematosus (SLE), blood concentrations of
HMGB1 correlate with disease activity.10
In patients with Crohn’s disease, a chronic inflam-
matory bowel disease (IBD), the blood concentration
of HMGB1 is higher than that in healthy subjects.11
Inflamed cells in the intestine release cytokines and
DAMPs, and HMGB1 can also be detected in the
faeces.12,13 Further evidence for the pro-inflammatory
actions of HMGB1 in IBD is derived from the finding
that inhibition of HMGB1 by neutralising anti-
HMGB1 Abs resulted in reduced inflammation in an
animal model of colitis and sepsis.14 The potential for
reversing and preventing the activation of innate
immunity by targeting HMGB1 in diverse models of
sterile and infection-induced conditions has been
reviewed by Andersson and Tracey.4
HMGB1 may act as an auto-Ag and induce the pro-
duction of anti-HMGB1 auto-Abs. These auto-Abs are
detected in a large proportion of patients with autoim-
mune diseases as well as healthy humans.15 The pro-
duction of Abs against highly conserved endogenous
proteins is rather unusual, and its potential role is not
fully understood.16 In SLE patients, Ab levels appear
to correlate with the SLE Disease Activity Index
(SLEDAI) and coincide with renal involvement.17,18
Interestingly, a study by Barnay-Verdier et al. indicated
that anti-HMGB1 Abs had protective functions against
septic shock and thus may represent an Ab-mediated
down-regulation of the immune response in autoim-
mune diseases.19 The ability of extracellular HMGB1
to induce the production of its own neutralising Abs
suggests an inherited negative feedback loop that limits
the level of innate immune activation.
Chronic fatigue, a condition characterised by ‘an
overwhelming sense of tiredness, lack of energy, and
feeling of exhaustion’, is common in all chronic inflam-
matory diseases.20 The biological definition of fatigue
is that fatigue is a part of sickness behaviour – a
response observed in animals during infections.
Sickness behaviour is generated in the brain when IL-
1b binds to specific IL-1 receptors on neurons. IL-1b
can pass from the periphery to the CNS across the
blood–brain barrier, or it can be produced in the
brain by activated microglia.21,22 Disulphide (ds)
HMGB1 and other DAMPs are among the molecules
that bind to TLR4 on macrophages and microglia and
stimulate proinflammatory cytokine production, thus
inducing sickness behaviour.7,23 TLR4-blocking pepti-
des are able to prevent this behaviour in animal stud-
ies.24 Another route for IL-1b production is through
fully reduced (fr) HMGB1, which binds to receptor for
advanced glycation end products (RAGE) on
macrophages and microglia and induces the release of
pro-inflammatory cytokines.
We hypothesise that anti-HMGB1 Abs down-
regulate HMGB1-driven immune activity leading to
lower IL-1b-driven macrophage and microglia activa-
tion and thus lower fatigue. We measured Abs in blood
against the redox variants dsHMGB1 and frHMGB1
and revealed a strong association with fatigue severity.
Patients and methods
Study participants
Fifty-seven patients with newly diagnosed and
untreated Crohn’s disease were consecutively recruited
from the Department of Gastroenterology at Stavanger
University Hospital. In addition, 28 healthy control
subjects among the hospital’s staff and their friends
and family members with no history of immunological
or neurological disease were recruited (Table 1). All
subjects were clinically examined, and they filled out
the fatigue visual analogue scale (fVAS) questionnaire
under supervision and guidance. The fVAS is a 100-
mm horizontal line with vertical anchors. The wording
on the left end (0 mm) is ‘No fatigue’ and on the right
end (100 mm) is ‘Fatigue as bad as it can be’. It is a
frequently used and widely accepted generic and unidi-
mensional fatigue instrument for rating fatigue in many
diseases.25
Disease activity measures
Disease activity in patients was assessed by C-reactive
protein (CRP) levels in blood, faecal (f-) calprotectin
levels, and by colonoscopic evaluation using the Simple
Endoscopic Score for Crohn’s disease (SES-CD).26
Laboratory tests
Routine laboratory tests were performed, including
tests for haemoglobin, white blood cell count and
thrombocytes. In addition, blood was drawn into
EDTA tubes, cooled on ice and centrifuged at 2800 g
for 15 min at 4C. Plasma was aliquoted and stored at
80C until further analysis.
ELISA for anti-HMGB1 auto-Abs
An in-house ELISA method for detection of Abs in
plasma against different redox isoforms of HMGB1
was performed as follows. Each Greiner Bio-One
(Frickenhausen, Germany) medium 96-well plate was
divided into three sections and coated overnight (4C)
with 50 ml dsHMGB1 (2 mg/ml), 50 ml frHMGB1 (2 mg/
ml) (HMGBiotech, Milan, Italy) in PBS (Thermo
Fisher Scientific, Rockford, IL) or pure PBS. After
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coating, the wells were blocked for 1 h with 300 ml 20%
FBS (GIBCO, Thermo Fisher Scientific) in PBS w/
0.05% Tween-20 (VWR Chemicals, Fontenay-sous-
Bois, France). Each plasma sample was diluted 1:25
in blocking solution before 50 ml of it was added in
triplicate to each of the three coatings and incubated
for 2 h. Blocking solution was used as a solvent blank,
and two different plasma samples were analysed on all
plates to determine the between-plate variation.
Secondary Ab (anti-polyvalent immunoglobulin (IgG,
A, M) peroxidase conjugate (A8400), 0.9 mg/ml;
Sigma–Aldrich, St Louis, MO) diluted 1:1000 in block-
ing buffer was added (100 ml/well) for 1 h incubation.
The wells were washed, and bound Ab was detected by
adding 100 ml OPD-solution (OPD-tablets (#34006)
and peroxide substrate buffer (#34062); Thermo
Fisher Scientific). The reaction was stopped with 100
ml 2 M H2SO4 (VWR Chemicals) after 30 min.
Incubations were performed at room temperature,
and each plate wash was repeated five times using
400 ml PBS w/0.05% Tween-20. Absorbance was mea-
sured at 490 nm (Gen5 plate reader; BioTek
Instruments, Winooski, VT).
Absorbance for non-specific binding measured in
PBS-coated wells was subtracted from the absorbance
measured in the Ag-coated wells. The remaining absor-
bance is a relative measure of the Ab level in each
sample. The limit of detection (LOD) for anti-
dsHMGB1 and anti-frHMGB1 Abs was calculated
from the mean absorbanceþ2.5 SD of the solvent
blank. Sample absorbance below the LOD was set to
LOD/2 for calculations. Between-plate variation was
assessed by comparing the mean absorbance of the
internal quality controls and found to be 15.3% and
17.8% for anti-dsHMGB1 and anti-frHMGB1 Abs,
respectively.
Statistical analysis
Normal distribution of the data was tested by using the
Shapiro–Wilk test. Demographic and clinical data are
reported as the mean  SD if normally distributed,
otherwise as median (range). Means of normally dis-
tributed data in patients versus those in healthy control
subjects were compared using a simple t-test, while
non-normally distributed data were compared by
using the Mann–Whitney U-test. The differences in cat-
egorical variables between the groups were analysed by
using the chi-square test.
When developing regression models, univariable
linear regression analyses were first performed using
fVAS scores as the dependent variable and age, sex,
Hb, CRP, f-calprotectin, SES-CD and the two different
anti-HMGB1 Abs as independent variables.
Independent variables with P< 0.2 (CRP, f-calprotec-
tin, SES-CD, anti-dsHMGB1 and anti-frHMGB1) in
addition to age and sex were then selected into the
multivariable regression models. As the anti-HMGB1
Ab variants showed high levels of intercorrelation, we
fitted two separate multivariable models: anti-
dsHMGB1 Abs and anti-frHMGB1 Abs, respectively.
Finally, backward stepwise selection models were fitted
to exclude non-significant independent variables.





subjects (n¼28) P Value
Age, yr 31 (16–78) 43 (23–66) 0.002
Male/female, n (%) 22 (38.6)/35 (61.4) 5 (17.9)/23 (82.1) 0.08
fVAS, scores (n¼ 56) 54.5 (1–98) 14 (2–56) < 0.001
Hb, g/l, M (SD) 12.3 (1.8)
CRP, mg/dl 8.4 (1.0–139)
F-calprotectin, mg/kg (n¼ 52) 338 (15–4432)
SES-CD 8 (1–37)




Anti-dsHMGB1 Absa 0.17 (0.04–1.32) 0.18 (0.04–1.41) 0.43
Anti-frHMGB1 Absa 0.04 (0.04–1.18) 0.04 (0.04–1.05) 0.58
Medians and ranges are given unless otherwise stated.
aAbsorbance at 490 nm.
dsHMGB1: disulphide high mobility group box 1 protein; f-calprotectin: faecal calprotectin; frHMGB1: fully reduced HMGB1; fVAS: fatigue visual
analogue scale; SES-CD: Simple Endoscopic Score for Crohn’s Disease.
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P-values < 0.05 were considered significant. The
analyses were performed using IBM SPSS Statistics
for Windows v26 (IBM Corp., Armonk, NY), and
the figures were made in RStudio 1.1.463 with R
v3.5.1 (The R Foundation for Statistical Computing,
Vienna, Austria).
Ethical considerations
This study was approved by the Norwegian Regional
Ethics Committee (REK 2011/2631) and carried out in
compliance with the principles outlined in the
Declaration of Helsinki. All patients provided written
informed consent to participate in the study. The study
was registered at ClinicalTrials.gov (NCT01551563).
Results
Baseline characteristics
Selected demographic and laboratory data are pre-
sented in Table 1. Patients were younger than the
healthy subjects and had higher fVAS scores. There
were no significant differences in the absorbance
levels of either anti-dsHMGB1 or anti-frHMGB1 Abs
between patients and healthy control subjects.
Fatigue and disease activity markers
No statistically significant associations occurred
between disease activity markers (SES-CD, f-calprotec-
tin and CRP) and fVAS scores in the univariable or
multivariable linear regression models (Tables 2 and 3).
Fatigue and anti-HMGB1 Abs
In univariable regression analysis, the increasing con-
centrations of Abs against both isotypes of HMGB1
were inversely associated with fVAS scores in the
patient group, whereas no associations were
found for healthy control subjects (Table 2 and
Figure 1a and b).
We performed multivariable regression analysis with
fVAS scores as the dependent variable and anti-
dsHMGB1 or anti-frHMGB1 Abs among the disease
activity independent variables (CRP, f-calprotectin and
SES-CD), age and sex. This yielded R2¼0.23, P¼ 0.07,
and R2¼ 0.21, P¼ 0.09, respectively, for the two
models (Table 3). Anti-HMGB1 ab levels for both var-
iants were strongly and inversely associated with fVAS
scores. Applying backward stepwise selection while
keeping the variables age and sex in the model, anti-
HMGB1 Abs were identified as the most contributing
factor for fVAS scores, yielding B¼29.10, P¼ 0.01,
R2¼ 0.17 for anti-dsHMGB1 Abs, and B¼17.77,
P¼ 0.01, R2¼ 0.17 for anti-frHMGB1 Abs.
Discussion
The main finding of this study is that high levels of
anti-HMGB1 auto-Abs in blood are associated with
less fatigue in patients with Crohn’s disease. This
observation supports the hypothesis that in inflamma-
tory conditions, fatigue, at least to some extent, is gen-
erated by pro-inflammatory cytokines and that
HMGB1 is involved in fatigue signalling pathways
and boosts this mechanism. Of the various known
pro-inflammatory cytokines, IL-1b has been shown to
be a central actor in fatigue generation. In the brain,
this molecule binds to a complex of the IL-1 receptor
type 1 (IL-1RI) and a brain subtype of the accessory
Table 2. Associations between fatigue (fVAS scores) and
selected demographic and laboratory variables in patients with
Crohn’s disease.
fVAS (n¼ 56)
B R2 P Value
Age, yr 0.24 0.02 0.27
Sex 8.93 0.03 0.20
Hb, g/l 1.61 0.01 0.41
CRP, mg/dl 0.17 0.05 0.09
F-calprotectin, mg/kg (n¼ 52) 0.01 0.04 0.15
SES-CD 0.63 0.04 0.13
Anti-dsHMGB1 Absa 30.99 0.14 0.005
Anti-frHMGB1 Absa 37.71 0.17 0.001
Univariable regression with fVAS as the dependent variable.
aAbsorbance at 490 nm.
Table 3. Multivariable regression models including age and sex
to show the effect of anti-HMGB1 Abs on fatigue severity.
fVAS (N¼ 56)
B P-value
Anti-dsHMGB1 Absa 27.17 0.03
Age, yr 0.28 0.26
Sex 6.35 0.40
CRP, mg/dl 0.04 0.77
F-calprotectin, mg/kg (n¼ 52) 0.002 0.63
SES-CD 0.45 0.46
Model summary R2¼ 0.23, P¼ 0.07
Anti-frHMGB1 Absa 15.40 0.04
Age, yr 0.26 0.29
Sex 8.25 0.26
CRP, mg/dl 0.03 0.81
F-calprotectin, mg/kg (n¼ 52) 0.001 0.83
SES-CD 0.47 0.44
Model summary R2¼ 0.21, P¼ 0.09
fVAS scores as the dependent variable. Multivariable regression model
before backward selection.
aAbsorbance at 490 nm.
Kvivik et al. 289
protein (AcP), the AcPb.27,28 This leads to neuronal
activation, which in turn induces sickness behaviour,
of which fatigue is a major component.
Therapeutic blockade of IL-1 alleviates fatigue in
patients with rheumatoid arthritis, diabetes type 2, prima-
ry Sj€ogren’s syndrome and cancer-related fatigue.29–32
HMGB1 activates macrophages and microglia to pro-
duce and release IL-1b. When anti-HMGB1 Abs are pre-
sent, lower amounts of HMGB1 is available for
stimulation of macrophages and microglia. Thus, lower
production and release of IL-1b and other pro-
inflammatory cytokines follows, and lower neuronal acti-
vation and sickness behaviour/fatigue is observed.
HMGB1 and anti-HMGB1 Abs therefore add to the net-
work of molecules that influence fatigue (Figure 2).33
To the best of our knowledge, this is the first study
to investigate the association between fatigue and
HMGB1 in humans. A few animal studies support
the fatigue-inducing effect of HMGB1. In a study by
Frank et al., administering dsHMGB1 directly into the
cerebrospinal fluid induced sickness behaviour with an
increase in the production of pro-inflammatory medi-
ators and increased expression of NF-jb mRNA in the
hippocampus. Similar effects were revealed in vitro in
microglia cells stimulated with dsHMGB1. However,
injection of frHMGB1 did not result in the same
effects.34 In another study, separate injections of
dsHMGB1 and frHMGB1 into the cerebral cortex of
rats initiated local inflammation characterised by
increased IL-1b production and significant blood–
brain barrier disruption.35 In a study by Morioka
et al., astrocytic TLR4 was activated after intrathecal
treatment with HMGB1 in mice, which led to increased
production of IL-1b and increased neuropathic pain.36
Fatigue after cerebral strokes is common. However,
the mechanisms involved are unclear. Increasing evi-
dence points to systemic inflammatory responses and
sickness behaviour induced by pro-inflammatory cyto-
kines as important factors in post-stroke fatigue.37 To
date, there are no human studies on the role of
HMGB1 in post-stroke fatigue. However, in an exper-
imental animal stroke model, it was observed that the
release of HMGB1 and signalling through RAGE con-
tributed to brain injury–induced sickness behaviour.
Anti-HMGB1 Ab treatment of the animals reduced
sickness behaviour, but it did not improve the infarct
volume or the outcome.38 These observations strength-
en the hypothesis on the role of HMGB1 in fatigue
generation.
In Crohn’s disease, intestinal inflammation is
believed to result from a complex interplay between
environmental factors and a dysregulated innate
immune system in a genetically predisposed individu-
al.39 Macrophages and monocytes at inflamed intesti-
nal sites are potential sources for the extracellular
secretion of DAMPs such as HMGB1, where
dsHMGB1 and frHMGB1 may act by binding to
TLR4 and RAGE receptors, respectively.40
HMGB1 can interact with several pathogen recog-
nition receptors to promote cell migration and cytokine
production, as well as act in complex with other
immune-stimulating molecules such as IL-1b, LPS
and DNA and enhance their pro-inflammatory
responses.41–44 HMGB1 appears to be involved in the
pathophysiology of IBD. McDonnell et al. reported
increased blood levels of HMGB1 in patients with
Crohn’s disease and ulcerative colitis, but they saw
no association with disease activity.11 Likewise, they
found no association between anti-HMGB1 Abs in
blood and disease activity markers (CRP, f-calprotectin
and SES-CD). However, a study that measured faecal
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Figure 1. Association between fatigue and levels of anti-
HMGB1 Ab variants. Univariable linear regression analysis in 56
patients with Crohn’s disease and 28 healthy control subjects,
using the fatigue visual analogue scale (fVAS) as the dependent
variable and anti-dsHMGB1 Abs (a) or anti-frHMGB1 Abs (b) as
the independent variable. For each group, a fitted regression line
is shown, continuous for patients and dotted for healthy control
subjects.
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A somewhat intriguing finding was that both
dsHMGB1 and frHMGB1 were strongly associated
with fatigue. We originally hypothesised that
dsHMGB1 may have a more central role in fatigue
through canonical binding to TLR4 on macrophages
and microglia and inducing IL-1b production and
release. We found that anti-frHMGB1 Abs were as
strongly associated with fatigue severity as were anti-
dsHMGB1 Abs. Whether this was due to frHMGB1
signalling through RAGE or oxidation of frHMGB1
by ROS to dsHMGB1 is unclear.46,47
There are several limitations to this study. First, we
did not measure the blood concentrations of HMGB1.
Doing so for the redox variants dsHMGB1 and
frHMGB1 in particular would have been interesting.
It is well known that anti-HMGB1 Abs interfere with
conventional ELISAs for HMGB1 measurements,48
and currently, no accurate and reliable method is avail-
able for measuring total HMGB1 or its redox
variants.49 Second, we did not measure the levels of
IL-1b or other molecules that are known to influence
fatigue severity or induce sickness behaviour. Third, we
found no difference in the anti-HMGB1 Ab
concentrations between healthy subjects and patients.
Our findings, after adjusting for non-specific binding
by subtracting absorbance from uncoated wells, are
opposed to those of Taikashi et al., who reported
higher levels in patients with Crohn’s disease.50
Whether the fine specificity of anti-HMGB1 Abs that
occurs in a disease state implies that these Abs have
functional activity as opposed to what is seen in healthy
states remains to be clarified. A fourth point that could
be discussed is the age difference between patients and
healthy subjects. However, in our experience, age does
not influence fatigue levels.51,52 We also find it unlikely
that the age difference observed would influence auto-
Ab levels significantly. A last point to consider is that
the secondary Ab in the assay captures all Ab isoforms.
It is possible that measures of specific isoforms could
have provided more information about their function
and source.
In conclusion, we found that the blood concentra-
tion of anti-HMGB1 Abs in patients with Crohn’s dis-
ease strongly influences the severity of fatigue. We
hypothesise that in acute and chronic inflammatory
conditions, anti-HMGB1 Abs down-regulate
Figure 2. A model for HMGB1-induced fatigue and sickness behaviour. Inflamed and damaged cells in the intestine release HMGB1
protein. HMGB1 activate macrophages by binding TLR4 and receptor for advanced glycation end-products (RAGE). This leads to
release of pro-inflammatory cytokines, including IL-1b. In the central nervous system, IL-1b binds to a complex of IL-1 type I (IL-1RI)
receptors and accessory protein (AcPb) on neuronal cells and induces sickness behaviour and fatigue. Anti-HMGB1 Abs bind HMGB1
and thus down-regulate HMGB1-induced fatigue. Created with BioRender.com.
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HMGB1-induced inflammation. This leads to lower
production of pro-inflammatory cytokines and lower
sickness behaviour and fatigue.
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